000137692 001__ 137692
000137692 005__ 20240229105115.0
000137692 0247_ $$2doi$$a10.1002/cam4.1782
000137692 0247_ $$2pmid$$apmid:30259714
000137692 037__ $$aDKFZ-2018-01569
000137692 041__ $$aeng
000137692 082__ $$a610
000137692 1001_ $$0P:(DE-He78)6ea02cd0867abd195dedd893b73bb513$$aYu, Haixin$$b0$$eFirst author$$udkfz
000137692 245__ $$aCirculating microRNA biomarkers for lung cancer detection in Western populations.
000137692 260__ $$aHoboken, NJ$$bWiley$$c2018
000137692 3367_ $$2DRIVER$$aarticle
000137692 3367_ $$2DataCite$$aOutput Types/Journal article
000137692 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660216393_27718$$xReview Article
000137692 3367_ $$2BibTeX$$aARTICLE
000137692 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000137692 3367_ $$00$$2EndNote$$aJournal Article
000137692 520__ $$aLung cancer (LC) is a leading cause of cancer-related death in the Western world. Patients with LC usually have poor prognosis due to the difficulties in detecting tumors at early stages. Multiple studies have shown that circulating miRNAs might be promising biomarkers for early detection of LC. We aimed to provide an overview of published studies on circulating miRNA markers for early detection of LC and to summarize their diagnostic performance in Western populations. A systematic literature search was performed in PubMed and ISI Web of Knowledge to find relevant studies published up to 11 August 2017. Information on study design, population characteristics, miRNA markers, and diagnostic accuracy (including sensitivity, specificity, and AUC) were independently extracted by two reviewers. Overall, 17 studies evaluating 35 circulating miRNA markers and 19 miRNA panels in serum or plasma were included. The median sensitivity (range) and specificity (range) were, respectively, 78.4% (51.7%-100%) and 78.7% (42.9%-93.5%) for individual miRNAs, and 83.0% (64.0%-100%) and 84.9% (71.0%-100%) for miRNA panels. Most studies incorporated individual miRNA markers as panels (with 2-34 markers), with multiple miRNA-based panels generally outperforming individual markers. Two promising miRNA panels were discovered and verified in prospective cohorts. Of note, both studies exclusively applied miRNA ratios when building up panels. In conclusion, circulating miRNAs may bear potential for noninvasive LC screening, but large studies conducted in screening or longitudinal settings are needed to validate the promising results and optimize the marker panels.
000137692 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000137692 588__ $$aDataset connected to CrossRef, PubMed,
000137692 7001_ $$0P:(DE-He78)e2927c4f5c050e0ad98ebb65eebe0d56$$aGuan, Zhong$$b1
000137692 7001_ $$0P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aCuk, Katarina$$b2
000137692 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3
000137692 7001_ $$0P:(DE-He78)d19149dd97b17ce55e70abd2f9e64d3d$$aZhang, Yan$$b4$$eLast author
000137692 773__ $$0PERI:(DE-600)2659751-2$$a10.1002/cam4.1782$$n10$$p4849-4862$$tCancer medicine$$v7$$x2045-7634$$y2018
000137692 909CO $$ooai:inrepo02.dkfz.de:137692$$pVDB
000137692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6ea02cd0867abd195dedd893b73bb513$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000137692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e2927c4f5c050e0ad98ebb65eebe0d56$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000137692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000137692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000137692 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d19149dd97b17ce55e70abd2f9e64d3d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000137692 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000137692 9141_ $$y2018
000137692 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER MED-US : 2015
000137692 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000137692 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000137692 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000137692 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000137692 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000137692 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000137692 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000137692 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000137692 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000137692 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000137692 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000137692 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000137692 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000137692 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000137692 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000137692 980__ $$ajournal
000137692 980__ $$aVDB
000137692 980__ $$aI:(DE-He78)C070-20160331
000137692 980__ $$aI:(DE-He78)G110-20160331
000137692 980__ $$aI:(DE-He78)L101-20160331
000137692 980__ $$aUNRESTRICTED